Format

Send to

Choose Destination
Clin Breast Cancer. 2018 Feb;18(1):e107-e113. doi: 10.1016/j.clbc.2017.07.016. Epub 2017 Aug 1.

Indications for Postmastectomy Radiation After Neoadjuvant Chemotherapy in ypN0 and ypN1-3 Axillary Node-Positive Women.

Author information

1
Department of Radiation Oncology, University of California, San Francisco, San Francisco, CA. Electronic address: Barbara.Fowble@ucsf.edu.
2
Department of Radiation Oncology, University of California, San Francisco, San Francisco, CA.
3
Division of Plastic and Reconstructive Surgery, University of California, San Francisco, San Francisco, CA.
4
Department of Surgery, Carol Frank Buck Breast Care Center, University of California, San Francisco, San Francisco, CA.
5
Department of Preventive and Restorative Dental Sciences, Department of Epidemiology and Biostatistics, University of California, San Francisco, San Francisco, CA.

Abstract

INTRODUCTION:

Downstaging with neoadjuvant chemotherapy (NAC) might obscure indications for postmastectomy radiation (PMRT). The degree of downstaging that results in local-regional recurrence (LRR) rates low enough to omit PMRT remains controversial. We examined the rate of LRR in women who received NAC who underwent mastectomy without PMRT.

PATIENTS AND METHODS:

Between 2004 and 2013, 81 women with stage I to IIIA breast cancer had NAC and mastectomy; 48 patients (59%) were clinical N0 and 33 patients (41%) were clinical N1; median age was 45 years; 33 patients (41%) had hormone receptor-positive (HR+)HER2-, 21 patients (26%) HR+HER2+, 19 patients (23%) HR- HER2-, and 7 patients (9%) HR-HER2+ disease. We explored how LRR rates varied with age, BRCA status, Grade, receptor status, clinical N status, pathologic response, lymphovascular invasion, and mastectomy margins. Median follow-up was 4.9 years.

RESULTS:

After NAC, 35 patients (43%) had a pathologic complete response (pCR), 33 patients (41%) were ypN0, and 13 patients (16%) were ypN1-3+. There were 8 LRRs (6 chest wall, 1 axillary, 1 supraclavicular node). The 5-year cumulative incidence of LRR was 8% for all patients, 3% for pCR, 16% for ypN0, 10% for ypN1-3+, 6% for HR+HER2-, 25% for HR+HER2+, 0% for HR-HER2-, and 0% for HR-HER2+. LRR was 31% in the ypN0 and 33% in the ypN1-3+ HR+HER2+ women, and 12% in the ypN0 and 0% in the ypN1 to ypN3+ HR+HER2- patients.

CONCLUSION:

This study is unique. All HER2+ patients received trastuzumab and LRR was analyzed according to treatment response, clinicopathologic factors, and receptor status. pCR patients including young women and clinical stage IIIA had low LRR rates. However, ypN0 and ypN1-3+ HR+HER2+ patients had higher rates of LRR compared with other receptor subgroups and on the basis of limited data should be considered for PMRT.

KEYWORDS:

Cancer chemotherapy; Mastectomy; Neoadjuvant chemotherapy; Postmastectomy radiation; Radiation therapy

PMID:
28830795
DOI:
10.1016/j.clbc.2017.07.016

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center